Why the study?
Does antiplatelet medication improve coagulation-fibrinolysis markers in chronic poststroke patients?
Does antiplatelet medication improve coagulation-fibrinolysis markers in chronic poststroke patients?
Antiplatelet therapy with aspirin or ticlopidine in chronic poststroke patients is associated with normalized levels of plasminogen activator inhibitor-1, suggesting a beneficial effect on the coagulation-fibrinolysis system.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice in chronic poststroke patients; hypothesis-generating for antiplatelet effects on fibrinolysis markers.
Tohgi et al. (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: